Rubella - Pipeline Review Market Growth, Trend & Analysis Report 2015 Radiant Insights, Inc
Summary Radiant Insights's, 'Rubella - Pipeline Review, H2 2015', provides an overview of the Rubella's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Rubella, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rubella and special features on late-stage and discontinued projects. Read Complete Report With TOC @ http://www.radiantinsights.com/research/rubella-pipeline-review-h2-2015 Radiant Insights's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Radiant Insights's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Radiant Insights's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Summary
Radiant Insights's, 'Rubella - Pipeline Review, H2 2015', provides an overview of the Rubella's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Rubella, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rubella and special features on late-stage and discontinued projects.
Read Complete Report With TOC @ http://www.radiantinsights.com/research/rubella-pipeline-review-h2-2015
Radiant Insights's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Radiant Insights's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Radiant Insights's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Rubella</strong> - <strong>Pipeline</strong> <strong>Review</strong> <strong>Market</strong> <strong>Growth</strong>, <strong>Trend</strong> & <strong>Analysis</strong><br />
<strong>Report</strong> <strong>2015</strong>: <strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />
Summary<br />
<strong>Radiant</strong> <strong>Insights</strong>'s, '<strong>Rubella</strong> - <strong>Pipeline</strong> <strong>Review</strong>, H2 <strong>2015</strong>', provides an overview of the <strong>Rubella</strong>'s<br />
therapeutic pipeline.<br />
This report provides comprehensive information on the therapeutic development for <strong>Rubella</strong>,<br />
complete with comparative analysis at various stages, therapeutics assessment by drug target,<br />
mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest<br />
updates, and featured news and press releases. It also reviews key players involved in the therapeutic<br />
development for <strong>Rubella</strong> and special features on late-stage and discontinued projects.<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/rubella-pipelinereview-h2-<strong>2015</strong><br />
<strong>Radiant</strong> <strong>Insights</strong>'s report features investigational drugs from across globe covering over 20 therapy<br />
areas and nearly 3,000 indications. The report is built using data and information sourced from<br />
<strong>Radiant</strong> <strong>Insights</strong>'s proprietary databases, Company/University websites, SEC filings, investor<br />
presentations and featured press releases from company/university sites and industry-specific third<br />
party sources, put together by <strong>Radiant</strong> <strong>Insights</strong>'s team. Drug profiles/records featured in the report<br />
undergoes periodic updation following a stringent set of processes that ensures that all the profiles are<br />
updated with the latest set of information. Additionally, processes including live news & deals<br />
tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent<br />
developments are captured on a real time basis.<br />
The report enhances decision making capabilities and help to create effective counter strategies to<br />
gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to<br />
produce first-in-class and best-in-class products.<br />
Scope<br />
- The report provides a snapshot of the global therapeutic landscape of <strong>Rubella</strong><br />
- The report reviews key pipeline products under drug profile section which includes, product<br />
description, MoA and R&D brief, licensing and collaboration details & other developmental activities<br />
- The report reviews key players involved in the therapeutics development for <strong>Rubella</strong> and enlists all<br />
their major and minor projects<br />
- The report summarizes all the dormant and discontinued pipeline projects<br />
- A review of the <strong>Rubella</strong> products under development by companies and universities/research<br />
institutes based on information derived from company and industry-specific sources<br />
- <strong>Pipeline</strong> products coverage based on various stages of development ranging from pre-registration till<br />
discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects<br />
- Coverage of the <strong>Rubella</strong> pipeline on the basis of target, MoA, route of administration and molecule<br />
type<br />
- Latest news and deals relating related to pipeline products<br />
Reasons To Buy<br />
- Provides strategically significant competitor information, analysis, and insights to formulate<br />
effective R&D development strategies<br />
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies<br />
to gain competitive advantage<br />
- Develop strategic initiatives by understanding the focus areas of leading companies<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/rubella-pipelinereview-h2-<strong>2015</strong><br />
- Identify and understand important and diverse types of therapeutics under development for <strong>Rubella</strong><br />
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline<br />
- Devise corrective measures for pipeline projects by understanding <strong>Rubella</strong> pipeline depth and focus<br />
of Indication therapeutics<br />
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with<br />
the most attractive projects to enhance and expand business potential and scope<br />
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors<br />
that drove them from pipeline<br />
Table of Contents<br />
Table of Contents 2<br />
List of Tables 5<br />
List of Figures 5<br />
Introduction 6<br />
<strong>Radiant</strong> <strong>Insights</strong> <strong>Report</strong> Coverage 6<br />
<strong>Rubella</strong> Overview 7<br />
Therapeutics Development 8<br />
<strong>Pipeline</strong> Products for <strong>Rubella</strong> - Overview 8
<strong>Pipeline</strong> Products for <strong>Rubella</strong> - Comparative <strong>Analysis</strong> 9<br />
<strong>Rubella</strong> - Therapeutics under Development by Companies 10<br />
<strong>Rubella</strong> - Therapeutics under Investigation by Universities/Institutes 11<br />
<strong>Rubella</strong> - <strong>Pipeline</strong> Products Glance 12<br />
Late Stage Products 12<br />
Clinical Stage Products 13<br />
Early Stage Products 14<br />
<strong>Rubella</strong> - Products under Development by Companies 15<br />
<strong>Rubella</strong> - Products under Investigation by Universities/Institutes 16<br />
<strong>Rubella</strong> - Companies Involved in Therapeutics Development 17<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/rubella-pipelinereview-h2-<strong>2015</strong><br />
Beijing Minhai Biotechnology Co., Ltd 17<br />
Beijing Tiantan Biological Products Co., Ltd. 18<br />
Biological E. Limited 19<br />
China National Pharmaceutical Group Corporation 20<br />
Daiichi Sankyo Company, Limited 21<br />
GlaxoSmithKline Plc 22<br />
Organic Vaccines 23<br />
Prometheon Pharma, LLC 24<br />
Sinovac Biotech Ltd. 25<br />
Zydus Cadila Healthcare Limited 26<br />
<strong>Rubella</strong> - Therapeutics Assessment 27<br />
Assessment by Monotherapy Products 27<br />
Assessment by Combination Products 28<br />
Assessment by Route of Administration 29<br />
Assessment by Molecule Type 31<br />
Drug Profiles 33
Cell Therapy for Measles, Mumps and <strong>Rubella</strong> - Drug Profile 33<br />
Product Description 33<br />
Mechanism of Action 33<br />
R&D Progress 33<br />
measles + mumps + rubella + varicella vaccine - Drug Profile 34<br />
Product Description 34<br />
Mechanism of Action 34<br />
R&D Progress 34<br />
measles + mumps + rubella + varicella vaccine - Drug Profile 35<br />
Product Description 35<br />
Mechanism of Action 35<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/rubella-pipelinereview-h2-<strong>2015</strong><br />
R&D Progress 35<br />
measles + mumps + rubella + varicella vaccine - Drug Profile 36<br />
Product Description 36<br />
Mechanism of Action 36<br />
R&D Progress 36<br />
measles + mumps + rubella vaccine - Drug Profile 37<br />
Product Description 37<br />
Mechanism of Action 37<br />
R&D Progress 37<br />
measles + mumps + rubella vaccine - Drug Profile 38<br />
Product Description 38<br />
Mechanism of Action 38<br />
R&D Progress 38<br />
measles + mumps + rubella vaccine - Drug Profile 39<br />
Product Description 39
Mechanism of Action 39<br />
R&D Progress 39<br />
measles + rubella + varicella vaccine - Drug Profile 40<br />
Product Description 40<br />
Mechanism of Action 40<br />
R&D Progress 40<br />
measles + rubella vaccine - Drug Profile 41<br />
Product Description 41<br />
Mechanism of Action 41<br />
R&D Progress 41<br />
measles + rubella vaccine - Drug Profile 42<br />
Product Description 42<br />
Mechanism of Action 42<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/rubella-pipelinereview-h2-<strong>2015</strong><br />
R&D Progress 42<br />
measles [strain schwarz] + mumps [strain RIT 4385] + rubella [strain wistar RA 27/3] vaccine - Drug<br />
Profile 43<br />
Product Description 43<br />
Mechanism of Action 43<br />
R&D Progress 43<br />
VN-0102 - Drug Profile 44<br />
Product Description 44<br />
Mechanism of Action 44<br />
R&D Progress 44<br />
<strong>Rubella</strong> - Recent <strong>Pipeline</strong> Updates 45<br />
<strong>Rubella</strong> - Dormant Projects 46<br />
Appendix 47<br />
Methodology 47
Coverage 47<br />
Secondary Research 47<br />
Primary Research 47<br />
Expert Panel Validation 47<br />
Contact Us 47<br />
Disclaimer 48<br />
List of Tables<br />
Number of Products under Development for <strong>Rubella</strong>, H2 <strong>2015</strong> 8<br />
Number of Products under Development for <strong>Rubella</strong> - Comparative <strong>Analysis</strong>, H2 <strong>2015</strong> 9<br />
Number of Products under Development by Companies, H2 <strong>2015</strong> 10<br />
Number of Products under Investigation by Universities/Institutes, H2 <strong>2015</strong> 11<br />
Comparative <strong>Analysis</strong> by Late Stage Development, H2 <strong>2015</strong> 12<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/rubella-pipelinereview-h2-<strong>2015</strong><br />
Comparative <strong>Analysis</strong> by Clinical Stage Development, H2 <strong>2015</strong> 13<br />
Comparative <strong>Analysis</strong> by Early Stage Development, H2 <strong>2015</strong> 14<br />
Products under Development by Companies, H2 <strong>2015</strong> 15<br />
Products under Investigation by Universities/Institutes, H2 <strong>2015</strong> 16<br />
<strong>Rubella</strong> - <strong>Pipeline</strong> by Beijing Minhai Biotechnology Co., Ltd, H2 <strong>2015</strong> 17<br />
<strong>Rubella</strong> - <strong>Pipeline</strong> by Beijing Tiantan Biological Products Co., Ltd., H2 <strong>2015</strong> 18<br />
<strong>Rubella</strong> - <strong>Pipeline</strong> by Biological E. Limited, H2 <strong>2015</strong> 19<br />
<strong>Rubella</strong> - <strong>Pipeline</strong> by China National Pharmaceutical Group Corporation, H2 <strong>2015</strong> 20<br />
<strong>Rubella</strong> - <strong>Pipeline</strong> by Daiichi Sankyo Company, Limited, H2 <strong>2015</strong> 21<br />
<strong>Rubella</strong> - <strong>Pipeline</strong> by GlaxoSmithKline Plc, H2 <strong>2015</strong> 22<br />
<strong>Rubella</strong> - <strong>Pipeline</strong> by Organic Vaccines, H2 <strong>2015</strong> 23<br />
<strong>Rubella</strong> - <strong>Pipeline</strong> by Prometheon Pharma, LLC, H2 <strong>2015</strong> 24<br />
<strong>Rubella</strong> - <strong>Pipeline</strong> by Sinovac Biotech Ltd., H2 <strong>2015</strong> 25
<strong>Rubella</strong> - <strong>Pipeline</strong> by Zydus Cadila Healthcare Limited, H2 <strong>2015</strong> 26<br />
Assessment by Monotherapy Products, H2 <strong>2015</strong> 27<br />
Assessment by Combination Products, H2 <strong>2015</strong> 28<br />
Number of Products by Stage and Route of Administration, H2 <strong>2015</strong> 30<br />
Number of Products by Stage and Molecule Type, H2 <strong>2015</strong> 32<br />
<strong>Rubella</strong> Therapeutics - Recent <strong>Pipeline</strong> Updates, H2 <strong>2015</strong> 45<br />
<strong>Rubella</strong> - Dormant Projects, H2 <strong>2015</strong> 46<br />
List of Figures<br />
Number of Products under Development for <strong>Rubella</strong>, H2 <strong>2015</strong> 8<br />
Number of Products under Development for <strong>Rubella</strong> - Comparative <strong>Analysis</strong>, H2 <strong>2015</strong> 9<br />
Number of Products under Development by Companies, H2 <strong>2015</strong> 10<br />
Comparative <strong>Analysis</strong> by Clinical Stage Development, H2 <strong>2015</strong> 13<br />
Comparative <strong>Analysis</strong> by Early Stage Products, H2 <strong>2015</strong> 14<br />
Assessment by Monotherapy Products, H2 <strong>2015</strong> 27<br />
Assessment by Combination Products, H2 <strong>2015</strong> 28<br />
Number of Products by Routes of Administration, H2 <strong>2015</strong> 29<br />
Number of Products by Stage and Routes of Administration, H2 <strong>2015</strong> 29<br />
Number of Products by Molecule Types, H2 <strong>2015</strong> 31<br />
Number of Products by Stage and Molecule Types, H2 <strong>2015</strong> 31<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/rubella-pipelinereview-h2-<strong>2015</strong><br />
About <strong>Radiant</strong> <strong>Insights</strong><br />
<strong>Radiant</strong> <strong>Insights</strong> is a platform for companies looking to meet their market research and business<br />
intelligence requirements. We assist and facilitate organizations and individuals procure market<br />
research reports, helping them in the decision making process. We have a comprehensive collection of<br />
reports, covering over 40 key industries and a host of micro markets. In addition to over extensive<br />
database of reports, our experienced research coordinators also offer a host of ancillary services such<br />
as, research partnerships/ tie-ups and customized research solutions.<br />
For More Information, Visit <strong>Radiant</strong> <strong>Insights</strong>
Contact:<br />
Michelle Thoras<br />
Corporate Sales Specialist, USA<br />
<strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />
Phone: 1-415-349-0054<br />
Toll Free: 1-888-202-9519<br />
Email: sales@radiantinsights.com<br />
Blog URL: http://www.radiantinsightsinc.blogspot.com
Change language